GlassScriptPhysician profile
Caitlin Adele Greenwood
NPI 1710231964
$3,209.50
in general payments reported to CMS, 2019-2025
20 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $695 · 2023: $718 · 2024: $532 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765 · Education: $78.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.03 |
| Education | $78.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.48 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $601.68 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $383.04 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $366.67 | 2023-2025 | Auvelity |
| Corium, LLC | $235.22 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $187.07 | 2021-2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $98.62 | 2022-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $87.57 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $81.36 | 2021-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $78.57 | 2021-2022 | |
| Lundbeck LLC | $66.23 | 2022-2024 | Rexulti |
| Alkermes, INC. | $62.93 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $59.61 | 2022 | |
| Supernus Pharmaceuticals, INC. | $56.51 | 2022-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $52.09 | 2023-2024 | Spravato |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.50 | 2025 | Cobenfy |
| Tris Pharma INC | $22.61 | 2021 | |
| Alfasigma USA, INC. | $21.77 | 2021 | |
| Bausch Health US, LLC | $21.63 | 2022 | |
| Adlon Therapeutics L.P. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Greenwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.